glp-1 news today pharma Giants Bet on Next-Generation Treatments to Sustain Growth GLP-1 Patents Are Fading -

Its a time when we councel patients to build up nutrition by focusing on nutrient-dense foods

At Cosmoprof North America in Las Vegas in July, several beauty brands said they were working on products specifically for people on weight loss drugs, suggesting a flood of products is in the works

Fourth - and most time-sensitive: the FDA published a proposed rule on April 30, 2026 proposing to exclude semaglutide and tirzepatide from the 503B Bulks List, with a public comment period closing June 29, 2026

Ethics declarations Competing interests The author declares associations with the following companies: Astra-Zeneca, Bristol-Myers Squibb, Merck Sharpe & Dohme, NovoNordisk and Sanofi-Aventis (advisory board membership

MTC describes its metabolic testing service as measuring resting metabolic rate to help inform personalized calorie and macronutrient goals

Talk to your healthcare provider about any side effect that bothers you or doesnt go away